Total Payments
$350,516
2024 Payments
$20,250
Companies
4
Transactions
157
Payment Breakdown by Category
Consulting$211,191 (60.3%)
Research$139,325 (39.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $211,191 | 149 | 60.3% |
| Unspecified | $139,325 | 8 | 39.7% |
Payments by Type
General
$211,191
149 transactions
Research
$139,325
8 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Merck Sharp & Dohme Corporation | $197,635 | 104 | $0 (2021) |
| E.R. Squibb & Sons, L.L.C. | $87,465 | 4 | $0 (2024) |
| Celltrion, Inc. | $51,860 | 4 | $0 (2023) |
| PFIZER INC. | $13,556 | 45 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $20,250 | 2 | E.R. Squibb & Sons, L.L.C. ($20,250) |
| 2023 | $69,210 | 3 | E.R. Squibb & Sons, L.L.C. ($67,215) |
| 2022 | $2,775 | 1 | Celltrion, Inc. ($2,775) |
| 2021 | $126,250 | 38 | Merck Sharp & Dohme Corporation ($96,735) |
| 2020 | $101,688 | 48 | Merck Sharp & Dohme Corporation ($79,600) |
| 2019 | $20,238 | 35 | Merck Sharp & Dohme Corporation ($18,025) |
| 2018 | $7,744 | 23 | PFIZER INC. ($4,469) |
| 2017 | $2,363 | 7 | PFIZER INC. ($2,363) |
All Payment Transactions
157 individual payment records from CMS Open Payments — Page 1 of 7
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 01/04/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | — | Cash or cash equivalent | $10,875.00 | Research |
| Study: Phase III Stage III Unresectable NSCLC Combo - A Phase 3, Randomized, Open-Label Study to Compare Nivolumab Plus Concurrent Chemoradiotherapy (CCRT) followed by Nivolumab plus Ipilimumab or Nivolumab plus CCRT Followed by Nivolumab vs CCRT followed by Dur • Category: Oncology | ||||||
| 01/04/2024 | E.R. Squibb & Sons, L.L.C. | — | — | Cash or cash equivalent | $9,375.00 | Research |
| Study: Ph II MORAb-202 in 2L Platinum Resistant Ovarian Cancer | ||||||
| 05/08/2023 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | — | Cash or cash equivalent | $62,760.00 | Research |
| Study: Phase III Stage III Unresectable NSCLC Combo - A Phase 3, Randomized, Open-Label Study to Compare Nivolumab Plus Concurrent Chemoradiotherapy (CCRT) followed by Nivolumab plus Ipilimumab or Nivolumab plus CCRT Followed by Nivolumab vs CCRT followed by Dur • Category: Oncology | ||||||
| 01/05/2023 | E.R. Squibb & Sons, L.L.C. | — | — | Cash or cash equivalent | $4,455.00 | Research |
| Study: Ph II MORAb-202 in 2L Platinum Resistant Ovarian Cancer | ||||||
| 01/05/2023 | Celltrion, Inc. | — | — | Cash or cash equivalent | $1,995.00 | Research |
| Study: CT-P16 3.1 | ||||||
| 01/05/2022 | Celltrion, Inc. | — | — | Cash or cash equivalent | $2,775.00 | Research |
| Study: CT-P16 3.1 | ||||||
| 12/07/2021 | Celltrion, Inc. | — | — | Cash or cash equivalent | $29,290.00 | Research |
| Study: CT-P16 3.1 | ||||||
| 12/07/2021 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $6,300.00 | General |
| Category: ONCOLOGY | ||||||
| 12/07/2021 | Merck Sharp & Dohme Corporation | LENVIMA (Drug) | Consulting Fee | Cash or cash equivalent | $3,540.00 | General |
| Category: ONCOLOGY | ||||||
| 12/07/2021 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $1,320.00 | General |
| Category: ONCOLOGY | ||||||
| 11/05/2021 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $5,520.00 | General |
| Category: ONCOLOGY | ||||||
| 11/05/2021 | Merck Sharp & Dohme Corporation | LENVIMA (Drug) | Consulting Fee | Cash or cash equivalent | $2,940.00 | General |
| Category: ONCOLOGY | ||||||
| 11/05/2021 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $1,200.00 | General |
| Category: ONCOLOGY | ||||||
| 10/06/2021 | Merck Sharp & Dohme Corporation | LENVIMA (Drug) | Consulting Fee | Cash or cash equivalent | $6,540.00 | General |
| Category: ONCOLOGY | ||||||
| 10/06/2021 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $3,960.00 | General |
| Category: ONCOLOGY | ||||||
| 10/06/2021 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $1,740.00 | General |
| Category: ONCOLOGY | ||||||
| 09/03/2021 | Merck Sharp & Dohme Corporation | LENVIMA (Drug) | Consulting Fee | Cash or cash equivalent | $3,450.00 | General |
| Category: ONCOLOGY | ||||||
| 09/03/2021 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $2,400.00 | General |
| Category: ONCOLOGY | ||||||
| 09/03/2021 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $1,475.00 | General |
| Category: ONCOLOGY | ||||||
| 08/02/2021 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $2,700.00 | General |
| Category: ONCOLOGY | ||||||
| 08/02/2021 | Merck Sharp & Dohme Corporation | LENVIMA (Drug) | Consulting Fee | Cash or cash equivalent | $2,500.00 | General |
| Category: ONCOLOGY | ||||||
| 08/02/2021 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
| Category: ONCOLOGY | ||||||
| 07/06/2021 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $4,100.00 | General |
| Category: ONCOLOGY | ||||||
| 07/06/2021 | Merck Sharp & Dohme Corporation | LENVIMA (Drug) | Consulting Fee | Cash or cash equivalent | $3,450.00 | General |
| Category: ONCOLOGY | ||||||
| 07/06/2021 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $950.00 | General |
| Category: ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Phase III Stage III Unresectable NSCLC Combo - A Phase 3, Randomized, Open-Label Study to Compare Nivolumab Plus Concurrent Chemoradiotherapy (CCRT) followed by Nivolumab plus Ipilimumab or Nivolumab plus CCRT Followed by Nivolumab vs CCRT followed by Dur | E.R. Squibb & Sons, L.L.C. | $73,635 | 2 |
| CT-P16 3.1 | Celltrion, Inc. | $51,860 | 4 |
| Ph II MORAb-202 in 2L Platinum Resistant Ovarian Cancer | E.R. Squibb & Sons, L.L.C. | $13,830 | 2 |
About Dr. Steven Kaplan, MD
Dr. Steven Kaplan, MD is a Diagnostic Radiology healthcare provider based in Princeton, New Jersey. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/13/2011. The National Provider Identifier (NPI) number assigned to this provider is 1942578323.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Steven Kaplan, MD has received a total of $350,516 in payments from pharmaceutical and medical device companies, with $20,250 received in 2024. These payments were reported across 157 transactions from 4 companies. The most common payment nature is "Consulting Fee" ($211,191).
Ad
Practice Information
- Specialty Diagnostic Radiology
- Location Princeton, NJ
- Active Since 12/13/2011
- Last Updated 09/26/2013
- Taxonomy Code 2085R0202X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1942578323
Products in Payments
- KEYTRUDA (Biological) $136,940
- OPDIVO (Biological) $73,635
- LENVIMA (Drug) $60,695
- XALKORI (Drug) $11,313
- IBRANCE (Drug) $2,244
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Diagnostic Radiology Doctors in Princeton
Dr. David Youmans, M.d, M.D
Diagnostic Radiology — Payments: $127,167
Diagnostic Radiology $127,167
Dr. Theresa Aquino, M.d, M.D
Diagnostic Radiology — Payments: $3,223
Diagnostic Radiology $3,223
Dr. Afzal Ahmed, M.d, M.D
Diagnostic Radiology — Payments: $1,923
Diagnostic Radiology $1,923
Dr. Dana Olson, M.d, M.D
Diagnostic Radiology — Payments: $199.98
Diagnostic Radiology $199.98
Richard Feinstein, Md, MD
Diagnostic Radiology — Payments: $117.21
Diagnostic Radiology $117.21
Dr. Gwen Guglielmi, M.d, M.D
Diagnostic Radiology — Payments: $112.50
Diagnostic Radiology $112.50